FDA Brief

Warning letters Drugs

FDA warning letter to

Sani-Care Salon Products, Inc.

High riskIssued Apr 24, 2024Posted Jun 25, 2024Division of Pharmaceutical Quality Operations II

FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.

What happened

FDA inspected the Cartersville, Georgia drug manufacturing facility from October 31 to November 3, 2023. The agency found that the company lacked adequate quality-unit oversight, water-system validation and monitoring, cleaning validation, stability studies and expiration dating, finished-product identity/strength/microbial testing, and component identity testing; it also used expired benzalkonium chloride in hand sanitizer batches. FDA acknowledged the company's December 12, 2023 response to the Form FDA 483.

What FDA found

  1. The quality unit did not adequately oversee manufacturing to ensure drug products met identity, strength, quality, and purity specifications.

    21 CFR 211.22
  2. Batch production records omitted significant manufacturing steps, and the water system used for drug production was not validated or adequately monitored.

    21 CFR 211.100(a)
  3. Cleaning verification and validation were inadequate, and equipment cleaning and maintenance procedures were lacking.

    21 CFR 211.67(a)
  4. The company lacked adequate stability studies to set expiration dates and did not label its hand sanitizers with an expiration date.

    21 CFR 211.137(a)
  5. The company did not test finished drug products for identity, strength, impurities, total microbial counts, or objectionable microorganisms and had not established finished-product specifications since November 2020.

    21 CFR 211.165(a) and 211.165(b)
  6. The company released active pharmaceutical ingredient based on a supplier certificate of analysis without establishing its reliability or performing identity testing, and it used expired benzalkonium chloride in hand sanitizer batches.

    21 CFR 211.84(d)(1) and 211.84(d)(2)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, including quality-unit remediation, water-system assessment, cleaning and stability improvements, and testing plans. If corrective actions cannot be completed in that time, the company must state the reasons for delay and a completion schedule.

Who should pay attention

  • retailers and distributors selling Sani-Care hand sanitizers
  • contract manufacturers making both drug and non-drug products
  • companies relying on supplier certificates of analysis for incoming ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk